Literature DB >> 48348

Combination of delta9-tetrahydrocannabinol with oxymorphone or pentobarbital: Effects on ventilatory control and cardiovascular dynamics.

R E Johnstone, P L Lief, R A Kulp, T C Smith.   

Abstract

Marijuana is widely used, yet few data concerning its actions combined with other drugs exist. Psychologic, respiratory and cardiovascular effects of delta9-tetrahydrocannabinol (THC), the active component of marijuana, combined with oxymorphone (OXM) or with pentobarbital (PBL), were studies in 15 healthy volunteers. Oxymorphone, 1.0 mg/70 kg, iv, caused sedation and ventilatory depression (minute ventilation: 24.9 plus or minus 11.9 SD to 14.1 plus or minus 4.9 1/min with PETCO2 held at 50 torr) in eight volunteers. TCH (27, 40, 60, 90, and 134 mug/kg, iv) increased sedation and further decreased ventilation with each TCH dose to 6.6 plus or minus 3.7 1/min after 134 mug/kg. The combination of OXM and THC decreased the CO2-ventilation slope from 2.23 to 0.88 1/min/torr. When THC, 134 mug/kg, was added to OXM, which alone caused no significant cardiovascular change, cardiac index (4.1 plus or minus 1.3 to 5.0 plus or minus 2.2 1/min/m-2) and heart rate (66 plus or minus 12 to 107 plus or minus 31 beats/min) significantly increased and total peripheral resistance (1,030 plus or minus 260 to 660 plus or minus 200 dynes-sec/cm-5) decreased. Heart rates exceeded 150 beats/min in two subjects after 27 and 134 mug/kg THC. Pentobarbital alone, 100 mg/70 kg, iv, caused no significant ventilatory or cardiovascular change. THC, after PBL pretreatment, induced hallucinations and anxiety in five of seven volunteers; four failed to complete all five doses of THC becuase of the severe psychologic effects. The combination of PBL and 40 to 134 mug/kg THC did not affect ventilation significantly. After PBL pretreatment, THC significantly increased heart rate (76 plus or minus 17 to 130 plus or minus 32 beats/min). Cardiac index also increased (3.8 plus or minus 0.8 to 5.6 plus or minus 1.9 1/min/m-2) and total peripheral resistance decreased (1,070 plus or minus 240 to 720 plus or minus 300 dynes-sec/cm-5). Three subjects developed heart rates esceeding 150 beats/min after 27, 27, and 90 mug/kg THC; in all three, heart rates fell from maximal value with a further dose of THC.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 48348     DOI: 10.1097/00000542-197506000-00009

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  11 in total

Review 1.  Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?

Authors:  Patrycja Kleczkowska; Irena Smaga; Małgorzata Filip; Magdalena Bujalska-Zadrozny
Journal:  Neurotox Res       Date:  2016-08-02       Impact factor: 3.911

2.  Therapeutic potential of opioid/cannabinoid combinations in humans: Review of the evidence.

Authors:  Shanna Babalonis; Sharon L Walsh
Journal:  Eur Neuropsychopharmacol       Date:  2020-04-06       Impact factor: 4.600

3.  Ventilatory-depressant effects of opioids alone and in combination with cannabinoids in rhesus monkeys.

Authors:  Peter F Weed; Lisa R Gerak; Charles P France
Journal:  Eur J Pharmacol       Date:  2018-05-26       Impact factor: 4.432

4.  [Delta(9)-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain].

Authors:  W Seeling; L Kneer; B Büchele; J E Gschwend; L Maier; C Nett; T Simmet; P Steffen; M Schneider; M Rockemann
Journal:  Anaesthesist       Date:  2006-04       Impact factor: 1.041

5.  Analysis of the respiratory effects of cannabinoids in rats.

Authors:  Karin Schmid; Nathalie Niederhoffer; Bela Szabo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-09-10       Impact factor: 3.000

6.  Effects of pentobarbital on upper airway patency during sleep.

Authors:  M Eikermann; D J Eckert; N L Chamberlin; A S Jordan; S Zaremba; S Smith; C Rosow; A Malhotra
Journal:  Eur Respir J       Date:  2009-12-23       Impact factor: 16.671

7.  Relative potency of intravenous oxymorphone compared to other µ opioid agonists in humans - pilot study outcomes.

Authors:  Shanna Babalonis; Sandra D Comer; Jermaine D Jones; Paul Nuzzo; Michelle R Lofwall; Jeanne Manubay; Kevin W Hatton; Robert A Whittington; Sharon L Walsh
Journal:  Psychopharmacology (Berl)       Date:  2021-06-01       Impact factor: 4.415

8.  Cannabis Extract CT-921 Has a High Efficacy-Adverse Effect Profile in a Neuropathic Pain Model.

Authors:  Elham Rouhollahi; Bernard A MacLeod; Alasdair M Barr; Ernest Puil
Journal:  Drug Des Devel Ther       Date:  2020-08-17       Impact factor: 4.162

Review 9.  Cannabis and Athletic Performance.

Authors:  Jamie F Burr; Christian P Cheung; Andreas M Kasper; Scott H Gillham; Graeme L Close
Journal:  Sports Med       Date:  2021-09-13       Impact factor: 11.136

10.  Non-medical Cannabis Self-Exposure as a Dimensional Predictor of Opioid Dependence Diagnosis: A Propensity Score Matched Analysis.

Authors:  Eduardo R Butelman; Angelo G I Maremmani; Silvia Bacciardi; Carina Y Chen; Joel Correa da Rosa; Mary Jeanne Kreek
Journal:  Front Psychiatry       Date:  2018-06-27       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.